How THC and CBD capsules move through the body in multiple sclerosis patients with pain
In a substudy of 23 MS patients, oral THC and CBD capsules showed large individual variation in blood levels at steady state, but pharmacokinetic profiles were similar to those previously reported in healthy volunteers.
Quick Facts
What This Study Found
Among 23 MS patients taking oral THC (max 22.5 mg/day), CBD (max 45 mg/day), or combination capsules, pharmacokinetic parameters showed considerable individual variation but were comparable to previous reports from healthy controls. Simulated parameters for THC (5 mg): Cmax 1.21 ng/mL, Tmax 2.68 h, half-life 2.75 h. For CBD (10 mg): Cmax 2.67 ng/mL, Tmax 0.10 h, half-life 4.95 h.
Key Numbers
23 MS patients (17 female, mean age 52); max doses 22.5 mg THC and 45 mg CBD daily divided into 3 doses; THC half-life 2.75 h; CBD half-life 4.95 h; no effect found on pain or spasticity outcomes; considerable placebo response
How They Did This
Pharmacokinetic substudy within a randomized, double-blinded, placebo-controlled trial of 134 MS patients. Blood samples from 23 patients (4 THC, 6 CBD, 4 THC+CBD, 9 placebo) were analyzed using UHPLC-MS/MS, with computerized modeling to estimate PK parameters at probable steady state.
Why This Research Matters
Patient-level pharmacokinetic data for oral cannabis capsules in MS patients is scarce. Understanding how these medications behave in real patients, not just healthy volunteers, is important for dosing guidance.
The Bigger Picture
The wide individual variation in how patients metabolize cannabis-based capsules highlights why standardized dosing may produce very different blood levels across patients, complicating clinical use.
What This Study Doesn't Tell Us
Very small substudy (23 patients, only 4 in THC group); no significant effect on pain or spasticity; substantial placebo response; maximum doses may be too low for therapeutic effect; PK parameters modeled rather than directly measured
Questions This Raises
- ?Would higher doses produce therapeutic effects?
- ?Does the wide pharmacokinetic variation explain why some patients respond to cannabis-based medicines and others do not?
Trust & Context
- Key Stat:
- THC half-life 2.75 h, CBD half-life 4.95 h
- Evidence Grade:
- Very small pharmacokinetic substudy within an RCT. Provides useful mechanistic data but limited by sample size.
- Study Age:
- 2024 study
- Original Title:
- Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial.
- Published In:
- Clinical and translational science, 17(1), e13685 (2024)
- Authors:
- Hansen, Julie Schjødtz(2), Boix, Fernando(2), Hasselstrøm, Jørgen Bo, Sørensen, Lambert Kristiansen, Kjolby, Mads, Gustavsen, Stefan, Hansen, Rikke Middelhede, Petersen, Thor, Sellebjerg, Finn, Kasch, Helge, Rasmussen, Peter Vestergaard, Finnerup, Nanna Brix, Saedder, Eva Aggerholm, Svendsen, Kristina Bacher
- Database ID:
- RTHC-05367
Evidence Hierarchy
Frequently Asked Questions
How did oral cannabis capsules behave in MS patients?
Blood levels varied substantially between individuals, but the overall pharmacokinetic profiles were similar to what has been seen in healthy volunteers. THC peaked around 2.7 hours after dosing with a half-life of about 2.75 hours, while CBD peaked faster with a longer half-life of about 5 hours.
Did the cannabis capsules help with MS symptoms?
No significant effect was found on pain or spasticity measures, though there was a considerable placebo response. The maximum doses used (22.5 mg THC, 45 mg CBD per day) may have been too low for therapeutic effects, and the substudy was very small.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05367APA
Hansen, Julie Schjødtz; Boix, Fernando; Hasselstrøm, Jørgen Bo; Sørensen, Lambert Kristiansen; Kjolby, Mads; Gustavsen, Stefan; Hansen, Rikke Middelhede; Petersen, Thor; Sellebjerg, Finn; Kasch, Helge; Rasmussen, Peter Vestergaard; Finnerup, Nanna Brix; Saedder, Eva Aggerholm; Svendsen, Kristina Bacher. (2024). Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial.. Clinical and translational science, 17(1), e13685. https://doi.org/10.1111/cts.13685
MLA
Hansen, Julie Schjødtz, et al. "Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial.." Clinical and translational science, 2024. https://doi.org/10.1111/cts.13685
RethinkTHC
RethinkTHC Research Database. "Pharmacokinetics and pharmacodynamics of cannabis-based medi..." RTHC-05367. Retrieved from https://rethinkthc.com/research/hansen-2024-pharmacokinetics-and-pharmacodynamics-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.